Search

Displaying results 9141 - 9150 of 10000 in total
  1. Drug

    Nitroxoline

    go.drugbank.com/drugs/DB01422
    Experimental

    It is a hydroxyquinoline derivative unrelated to other classes of drugs.[A179251] Nitroxoline is active against bacterial gyrases.

  2. Drug

    Brazikumab

    go.drugbank.com/drugs/DB16115
    Investigational

    Brazikumab is under investigation in clinical trial NCT03759288 (An Active and Placebo-controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease).

  3. Drug

    Eltanexor

    go.drugbank.com/drugs/DB16153
    Investigational

    Eltanexor is under investigation in clinical trial NCT02649790 (Study of the Safety, Tolerability and Efficacy of KPT-8602 in Patients With Relapsed/refractory Cancer Indications).

  4. Drug

    Foralumab

    go.drugbank.com/drugs/DB16170
    Investigational

    Foralumab is under investigation in clinical trial NCT03291249 (Assessment of the Safety of Foralumab, an Oral Anti-cd3 Antibody, in Patients With NASH and T2DM).

  5. Drug

    Lutikizumab

    go.drugbank.com/drugs/DB16224
    Investigational

    Lutikizumab is under investigation in clinical trial NCT02087904 (A Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee Osteoarthritis).

  6. Drug

    Milvexian

    go.drugbank.com/drugs/DB16233
    Investigational

    Milvexian is under investigation in clinical trial NCT03766581 (A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel).

  7. Drug

    Tilsotolimod

    go.drugbank.com/drugs/DB16341
    Investigational

    Tilsotolimod is under investigation in clinical trial NCT03865082 (Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)).

  8. Drug

    WP-1122

    go.drugbank.com/drugs/DB17192
    Investigational

    It was granted FDA orphan designation for the treatment of glioblastoma multiforme.[L47361]

  9. Drug

    ATX-F8-117

    go.drugbank.com/drugs/DB17712
    Experimental

    Developed by Apitope, it is being investigated for the treatment of hemophilia A.[L46163]

  10. Drug

    BHV-5000

    go.drugbank.com/drugs/DB17817
    Experimental

    BHV-5000 is an orally bioavailable, low-trapping, potent N-methyl-D-aspartate (NMDA) receptor antagonist. The active metabolite of BHV-5000 is [lanicemine].[L46446]